A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer
Primary Sponsor
Victorian Comprehensive Cancer Centre (VCCC)
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG)
Accrual Target
32
Final Accrual
32
Closing Date of Accrual
22 November 2022
Trial Chairperson
Dr Steven David, Peter MacCallum Cancer Centre, VIC
Related Post
14 October, 2026
New FET-PET imaging approach helps target radiotherapy for glioblastoma, FIG trial – TROG 18.06 finds
LATEST NEWS: 14 October 2026 Adding a FET-PET brain
26 September, 2026
Trial finds radiation therapy halves risk of brain tumour recurrence after surgery
LATEST NEWS: 26 September 2026 Giving radiotherapy after surgery